Cargando…
Comparison of two doses of leucovorin in severe low-dose methotrexate toxicity – a randomized controlled trial
BACKGROUND: Leucovorin (folinic acid) is a commonly used antidote for severe toxicity with low-dose methotrexate, but its optimum dose is unclear, varying from 15 to 25 mg every 6-h. METHODS: Open-label RCT included patients with severe low-dose (≤ 50 mg/week) methotrexate toxicity defined as WBC ≤ ...
Autores principales: | Bhargava, Mudit, Kopp, Chirag Rajkumar, Naidu, Shankar, Dhibar, Deba Prasad, Saroch, Atul, Khadwal, Alka, Narang, Tarun, Jain, Siddharth, Khullar, Aastha, Leishangthem, Bidya, Sharma, Aman, Kumar, Susheel, Sharma, Shefali, Jain, Sanjay, Dhir, Varun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197821/ https://www.ncbi.nlm.nih.gov/pubmed/37208770 http://dx.doi.org/10.1186/s13075-023-03054-2 |
Ejemplares similares
-
Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study
por: Sharma, Shefali Khanna, et al.
Publicado: (2020) -
Tocilizumab in COVID-19: finding the optimal route and dose
por: Jain, Siddharth, et al.
Publicado: (2020) -
Clinical, Biochemical Characteristics and Hospital Outcome of Acute Intermittent Porphyria Patients: A Descriptive Study from North India
por: Kumar, Susheel, et al.
Publicado: (2017) -
Predictors of COVID-19 severity and outcomes in Indian patients with rheumatic diseases: a prospective cohort study
por: Mathew, Jithin, et al.
Publicado: (2023) -
Comparison between methotrexate and apremilast in Psoriatic Arthritis-a single blind randomized controlled trial (APREMEPsA study)
por: Samanta, Joydeep, et al.
Publicado: (2023)